Sickle Cell PCR PND

 This test uses DNA-based polymerase chain reaction (PCR) techniques to detect mutations in the HBB gene responsible for sickle cell disease. When performed prenatally, it helps identify whether the fetus has inherited one or two copies of the mutant gene.

 It’s typically offered to pregnant women when both parents are known carriers of the sickle cell trait or when there’s a family history of the disease. It’s an essential part of prenatal screening to prepare for or manage potential outcomes.

 The test is performed on fetal DNA, usually obtained through procedures like chorionic villus sampling (CVS) or amniocentesis. These are conducted between 10–20 weeks of pregnancy, depending on the method used.

 If the fetus inherits two mutated genes (one from each parent), it is likely to develop sickle cell disease. If only one gene is inherited, the fetus is a carrier but generally healthy. A negative result indicates that the fetus has not inherited the mutation.

 While the genetic testing itself is highly accurate, the sample collection procedures carry a small risk of miscarriage. However, the benefit is the ability to make informed decisions about medical care or pregnancy management.